SPN and marginal zone lymphoma: The predictive algorithm correctly classified 83 out of 86 (97%) patients in the WM group and 33 out of 40 (83%) patients in the MZL group based on the selected markers, including percentages of CD43, FMC7, CD38, CD13, and MFI of CD19, FMC7, CD22, CD27 and CD79b.